News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
272,650 Results
Type
Article (14466)
Company Profile (281)
Press Release (257902)
Multimedia
Podcasts (59)
Webinars (9)
Section
Business (79639)
Career Advice (153)
Deals (13263)
Drug Delivery (35)
Drug Development (50537)
Employer Resources (31)
FDA (5764)
Job Trends (5149)
News (144650)
Policy (10048)
Tag
Academia (916)
Accelerated approval (5)
Adcomms (14)
Allergies (60)
Alliances (21760)
ALS (83)
Alzheimer's disease (919)
Antibody-drug conjugate (ADC) (130)
Approvals (5799)
Artificial intelligence (157)
Autoimmune disease (26)
Automation (6)
Bankruptcy (105)
Best Places to Work (4559)
BIOSECURE Act (6)
Biosimilars (59)
Biotechnology (231)
Bladder cancer (70)
Brain cancer (28)
Breast cancer (215)
Cancer (1956)
Cardiovascular disease (146)
Career advice (135)
Career pathing (2)
CAR-T (151)
CDC (4)
Cell therapy (403)
Cervical cancer (10)
Clinical research (41861)
Collaboration (716)
Company closure (1)
Compensation (367)
Complete response letters (19)
COVID-19 (1055)
CRISPR (63)
C-suite (239)
Cystic fibrosis (89)
Data (2212)
Denatured (13)
Depression (50)
Diabetes (179)
Diagnostics (1317)
Digital health (3)
Diversity (3)
Diversity, equity & inclusion (9)
Drug discovery (107)
Drug pricing (33)
Drug shortages (3)
Duchenne muscular dystrophy (144)
Earnings (30493)
Editorial (20)
Employer branding (4)
Employer resources (29)
Events (49588)
Executive appointments (553)
FDA (6775)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (628)
Gene editing (127)
Generative AI (11)
Gene therapy (336)
GLP-1 (417)
Government (1104)
Grass and pollen (2)
Guidances (96)
Healthcare (6602)
HIV (12)
Huntington's disease (29)
IgA nephropathy (39)
Immunology and inflammation (118)
Immuno-oncology (7)
Indications (25)
Infectious disease (1130)
Inflammatory bowel disease (125)
Inflation Reduction Act (9)
Influenza (25)
Intellectual property (87)
Interviews (18)
IPO (7314)
IRA (11)
Job creations (865)
Job search strategy (127)
Kidney cancer (8)
Labor market (12)
Layoffs (225)
Leadership (4)
Legal (1393)
Liver cancer (34)
Longevity (8)
Lung cancer (271)
Lymphoma (144)
Machine learning (6)
Management (7)
Manufacturing (204)
MASH (80)
Medical device (2614)
Medtech (2615)
Mergers & acquisitions (6387)
Metabolic disorders (489)
Multiple sclerosis (67)
NASH (13)
Neurodegenerative disease (104)
Neuropsychiatric disorders (32)
Neuroscience (1466)
NextGen: Class of 2025 (2021)
Non-profit (856)
Now hiring (24)
Obesity (228)
Opinion (105)
Ovarian cancer (86)
Pain (59)
Pancreatic cancer (89)
Parkinson's disease (153)
Partnered (8)
Patents (188)
Patient recruitment (127)
Peanut (38)
People (25959)
Pharmaceutical (47)
Pharmacy benefit managers (5)
Phase I (14793)
Phase II (19473)
Phase III (12292)
Pipeline (1148)
Policy (67)
Postmarket research (853)
Preclinical (6283)
Press Release (30)
Prostate cancer (87)
Psychedelics (41)
Radiopharmaceuticals (220)
Rare diseases (373)
Real estate (1425)
Recruiting (12)
Regulatory (8944)
Reports (18)
Research institute (943)
Resumes & cover letters (17)
Rett syndrome (8)
RNA editing (12)
RSV (11)
Schizophrenia (80)
Series A (119)
Series B (81)
Service/supplier (1)
Sickle cell disease (50)
Special edition (13)
Spinal muscular atrophy (118)
Sponsored (13)
Startups (1985)
State (1)
Stomach cancer (5)
Supply chain (26)
Tariffs (15)
The Weekly (45)
Vaccines (255)
Venture capital (41)
Weight loss (116)
Women's health (17)
Worklife (2)
Date
Today (65)
Last 7 days (281)
Last 30 days (1072)
Last 365 days (18414)
2025 (10828)
2024 (20550)
2023 (22416)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (151)
Alabama (52)
Alaska (2)
Arizona (56)
Arkansas (5)
Asia (17638)
Australia (2990)
California (4889)
Canada (1386)
China (494)
Colorado (181)
Connecticut (180)
Delaware (141)
Europe (37899)
Florida (618)
Georgia (151)
Hawaii (2)
Idaho (16)
Illinois (291)
India (13)
Indiana (116)
Iowa (7)
Japan (126)
Kansas (67)
Kentucky (6)
Louisiana (4)
Maine (11)
Maryland (563)
Massachusetts (3925)
Michigan (86)
Minnesota (184)
Mississippi (3)
Missouri (25)
Montana (14)
Nebraska (4)
Nevada (21)
New Hampshire (14)
New Jersey (1204)
New Mexico (12)
New York (1294)
North Carolina (638)
North Dakota (6)
Northern California (2202)
Ohio (134)
Oklahoma (9)
Oregon (21)
Pennsylvania (919)
Puerto Rico (7)
Rhode Island (21)
South America (209)
South Carolina (6)
Southern California (1874)
Tennessee (29)
Texas (601)
United States (16628)
Utah (70)
Virginia (106)
Washington D.C. (36)
Washington State (421)
West Virginia (1)
Wisconsin (26)
272,650 Results for "spyre therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Spyre Therapeutics to Participate in Upcoming June Investor Conferences
May 28, 2025
·
1 min read
Press Releases
Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 8, 2025
·
15 min read
Press Releases
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
February 25, 2025
·
1 min read
Genetown
Spyre Therapeutics to Participate in the Jefferies Global Healthcare Conference
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”) today announced that management will participate in a fireside chat and investor meetings at the Jefferies Global Healthcare Conference.
May 29, 2024
·
1 min read
Genetown
Spyre Therapeutics Announces Grants of Inducement Awards - June 03, 2024
Spyre Therapeutics, Inc. announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 83,000 shares of common stock of Spyre to 3 non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended.
June 3, 2024
·
1 min read
Genetown
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics, Inc. announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 90,100 shares of common stock of Spyre to 3 non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc.
April 1, 2024
·
1 min read
Genetown
Spyre Therapeutics Announces Grants of Inducement Awards - May 03, 2024
Spyre Therapeutics, Inc. announced that Spyre’s independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 126,000 shares of common stock of Spyre to 4 non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc.
May 3, 2024
·
1 min read
Press Releases
Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts
June 17, 2025
·
14 min read
Press Releases
Spyre Therapeutics Added to the Nasdaq Biotechnology Index
December 19, 2024
·
1 min read
Press Releases
Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025
June 17, 2025
·
1 min read
1 of 27,265
Next
